drugset / Trial / NCT00001269

Phase I Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Plus GM-CSF (Granulocyte-Macrophage Colony Stimulating Factor) Plus Dose Escalation of IL-3 (Interleukin-3) in Metastatic Breast Cancer

NCT00001269 ↗

Phase 1 Completed 100 enrolled National Cancer Institute (NCI)
Treatment

Summary

This is a phase I study to determine the maximal tolerated dose of IL-3 given alone or sequentially with GM-CSF following FLAC chemotherapy in metastatic breast cancer patients.

Timeline

Start
1991-05
Primary completion
—
Completion
2001-02

Drugs

EvaluationDrugModalityDoseRoute
Subject IL-3 Unknown — —